Malignant neoplasm of endocervix
ICD-10 C53.0 is a billable code used to indicate a diagnosis of malignant neoplasm of endocervix.
C53.0 refers to malignant neoplasms located in the endocervix, which is the canal that leads from the cervix to the uterus. This type of cancer is often associated with human papillomavirus (HPV) infection, which is a significant risk factor. Symptoms may include abnormal vaginal bleeding, pelvic pain, and unusual discharge. Diagnosis typically involves a Pap smear followed by a biopsy to confirm malignancy. Staging of endocervical cancer is crucial for determining treatment options and prognosis. The FIGO (International Federation of Gynecology and Obstetrics) staging system is commonly used, categorizing the cancer from Stage I (localized) to Stage IV (advanced). CA-125, a tumor marker, may be elevated in cases of endocervical cancer, although it is not specific to this type of cancer. Treatment often involves surgical approaches such as conization, hysterectomy, or radical hysterectomy, depending on the stage and extent of the disease. Adjuvant therapies may include radiation and chemotherapy, particularly in advanced stages.
Detailed surgical notes, pathology reports, and staging information are essential.
Diagnosis and treatment planning for endocervical cancer, follow-up care after surgery.
Ensure accurate staging and documentation of any adjuvant therapies.
Comprehensive biopsy reports and histological findings.
Evaluation of cervical biopsies for malignancy.
Pathology reports must clearly indicate the presence of malignancy and tumor characteristics.
Performed for Stage I endocervical cancer.
Operative report detailing the procedure and findings.
Ensure alignment with oncological guidelines for staging.
Common symptoms include abnormal vaginal bleeding, pelvic pain, and unusual discharge. However, many cases may be asymptomatic in early stages.
